Study Evaluating Autoimmune Hemolytic Anemia and Its Impact on Antiphospholipid Syndrome in Adults

What this Trial Is About

Autoimmune hemolytic anemia AIHA is a varied autoimmune condition causing low red blood cell counts with differing severity and health impacts. Antiphospholipid syndrome APS involves blood clotting problems and pregnancy-related complications linked to persistent antiphospholipid antibodies. AIHA occurs in about 10-12% of APS cases and is connected with serious complications like arterial clots, heart valve disease, and neurological symptoms, leading to a more severe APS form. The study aims to define the clinical impact of AIHA within APS, focusing on thrombosis, organ damage, and patient outcomes. It compares APS patients with AIHA to those without AIHA, using diagnostic blood tests such as hemoglobin levels and Coombs test to identify hemolysis and autoimmune involvement. Participants are grouped based on presence or absence of hemolysis evidence. Participants will be monitored for thrombotic events as the main outcome, with blood samples collected to assess hemoglobin and Coombs test status. The study uses randomization without masking to assign participants to groups. The involvement includes diagnostic testing and clinical evaluations, with the primary measure being the number of thrombotic events among APS patients with AIHA at baseline. The study is conducted over multiple years to thoroughly assess clinical implications.

Autoimmune Hemolytic Anemia and Its Clinical Implication on Antiphospholipid Syndrome